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Belfast, UK; and 8Cochrane Ireland, National University of Ireland Galway, Galway, IrelandIntroduction: Kidney transplant recipients are at increased susceptibility to many viral infections leading to
justifiable anxiety about the effects of coronavirus disease 2019 (COVID-19).
Methods: We performed literature searches from multiple resources in April and August 2020 for relevant
English and Chinese literature. Abstracts were screened, followed by full-text review with data extraction
of reports that included at least 20 kidney transplant recipients with confirmed severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection and completed outcomes.
Results: Twenty studies had sufficient data, which we have summarized. Studies were predominantly
descriptive and came from France, Italy, Spain, Turkey, United Kingdom, and United States. Quality
assessment demonstrated limitations in selection of comparison groups and controlling for additional
factors. Mortality rates from published studies were variable. Based on early data early from Spain, 46% of
patients who developed COVID-19 within 60 days of transplantation died. Acute kidney injury was com-
mon, and mycophenolate was discontinued in most patients.
Conclusion: Given the rapid global spread of COVID-19, reliable evidence is needed to inform public health
policies. Hospitalized kidney transplant recipients with COVID-19 are at a high risk of death in early reports
but interpretation of these data requires caution, as studies were susceptible to period effects. Reassur-
ingly, the quality of observational data is improving. Detailed and comprehensive data collection through
linked registries will be necessary to conduct accurate analyses of risk factors for adverse outcomes, not
least given the risks of stopping imunosuppression. This report highlights the early mortality excess in
transplant recipients but medium- and longer-term outcomes remain uncertain and merit careful
investigation.
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n December 31, 2019, the Wuhan Health Com-
mission in China reported an outbreak of atypical
pneumonia to the World Health Organization. The
causative pathogen was found to be the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) capable of human-to-human transmission through
respiratory droplets.1 The associated disease was
named COVID-19, and its spectrum of severity ranges
from no symptoms to life-threatening organspondence: Viyaasan Mahalingasivam, Renal Unit, Whipps
University Hospital, Barts Health NHS Trust, Whipps Cross
London, E11 1NR, UK. E-mail: viyaasan.mahalingasivam@
et
ved 3 July 2020; revised 25 September 2020; accepted 21
er 2020; published online 3 November 2020dysfunction, the scale of which can place extreme
burden on health care resources without control of
transmission.2 After spread across several continents,
COVID-19 was declared a pandemic by the World
Health Organization on March 11, 2020.
Severe lung injury and other organ-threatening com-
plications in COVID-19 are understood to be the result of a
dysregulated systemic inflammatory response in the days
after infection, leading to some immunosuppressive
therapies being repurposed both inside and out of clinical
trial settings in conventional management.3–5 Only low-
dose dexamethasone has so far demonstrated mortality
benefit compared with usual practice.6
Immunosuppressant drugs used to prevent allograft
rejection render kidney transplant recipients at increased
susceptibility to many viral infections, and suchKidney International Reports (2021) 6, 24–45
V Mahalingasivam et al.: COVID-19 and Kidney Transplantation CLINICAL RESEARCHinfections are an important cause of morbidity and mor-
tality in this population.7 The immune response to SARS-
CoV-2 infection in immunosuppressed kidney transplant
recipients, many with other comorbidities, may result in
differences in presentation, outcomes, and therapeutic
responses compared with the general population.
Given the rapid and global spread of COVID-19,
there is a need to gather evidence and disseminate as
quickly as possible. Our aim was to conduct a complete
systematic review of the early literature to synthesize,
analyze, and appraise what has been learned so far to
help clinicians and policy makers better understand the
risks to kidney transplant recipients, as well as identify




Inclusion and exclusion criteria were formulated to
ensure comprehensive searching and screening for ar-
ticles relevant to COVID-19 in chronic kidney disease,
specifically including kidney transplantation. Variables
of interest were defined based on the PICOS (patient/
population, intervention, comparison, outcomes, study
designs) strategy.8 Our protocol was prospectively
published via PROSPERO (CRD42020182134).
Initial searches were conducted on April 28, 2020,
including all relevant English- and Chinese-language
research up to that date from December 1, 2019; pa-
pers not written in these languages were excluded
because of a lack of resources to obtain timely trans-
lation. Published and nonpublished literature was
searched on MEDLINE (Ovid), EMBASE (Ovid), China
National Knowledge Infrastructure, the Wanfang
database, the Chinese Biomedical Literature Database,
clinicaltrials.gov, the Chinese Clinical Trial Register,
the World Health Organization database of COVID-19
research, and the Chinese Medical Journal Network.
Search terms are listed in Supplementary Material S1.
An updated search was deemed necessary due to the
rapidly evolving evidence base and was conducted
onAugust 4, 2020, via MEDLINE (Ovid), EMBASE
(Ovid), World Health Organization COVID19 database,
and bioRxiv and medRxiv preprint servers. The
strategy for the update searches is attached in
Supplementary Material S2.
Screening, Data Extraction, and Quality
Assessment
Duplicates were removed from the studies generated by
both searches and the remaining studies were imported
to the SysRev Platform (https://sysrev.com). Screening
was undertaken at abstract level by separate teams of 2
independent authors for both English and Chinese; aKidney International Reports (2021) 6, 24–45senior author adjudicated where there was non-
concordance. Reference lists were hand-searched for
any additional studies that may have been missed. Full-
text articles were then further assessed for eligibility,
including the exclusion of case reports or studies with
populations of interest of fewer than 20 confirmed
cases. As all studies were observational, further quality
assessment was undertaken using the Newcastle-
Ottawa Quality Assessment Scale.9 Where articles did
not report all outcomes specifically in kidney trans-
plant populations, we contacted authors to request
disaggregated data (Supplementary Material S3).
Data were extracted for each included study,
including online publication date, study population,
timeframe, total number of cases (including how many
patients had completed outcomes, that is, death or re-
covery to discharge), patient characteristics, clinical
presentation, outcomes, baseline immunosuppression
adjustment, and COVID-19 therapy. Inpatient mortality
for each study was calculated as a proportion of pa-
tients with completed outcomes.
RESULTS
Study Identification
The PRISMA flow diagram is shown in Figure 1. A total
of 1377 studies were identified through database
searching, after which 762 remained after de-
duplication; of these, a further 695 were excluded af-
ter abstract screening, leaving 65 that met criteria for
full-text assessment for eligibility with no additional
articles identified after hand-searching reference lists.
A further 47 studies were excluded after detailed
assessment. To be more comprehensive, we included 2
additional studies published shortly after our search
was completed.10,11 In total, 20 studies underwent data
extraction.
Quality Assessment
There were no randomized controlled trials or case-
control studies. Comparative analysis between
different exposure groups was limited. Sánchez-Ála-
varez et al.12 was a report from a national COVID-19
registry across Spain, whereas Pascual et al.13 and
Pérez-Sáez et al.14 reported on subgroups from this
registry (those within 60 days of transplantation, and
those treated with tocilizumab respectively). Bell
et al.15 and Ravanan et al.11 reported from national
transplant registries in Scotland and England, respec-
tively, whereas Manganaro et al.16 reported on from a
regional registry in Italy. Kates et al.10 reported on data
entered to a registry by more than 50 transplant cen-
ters, almost all from the United States, whereas Cravedi
et al.17 was a report of a consortium registry of 12
transplant centers across the United States, Italy, and25
Records identified through search 1
28 April 2020
(n = 812)
Records identified through search 2
04 August 2020
(n = 565)



















































Figure 1. PRISMA flow diagram.
CLINICAL RESEARCH V Mahalingasivam et al.: COVID-19 and Kidney TransplantationSpain. Boyarsky et al.18 and Vistoli et al.19 were cross-
sectional reports of national surveys from the United
States and Italy, respectively. The remaining studies
were either single-center or small multicenter case se-
ries of either inpatients, or both inpatient and outpa-
tient kidney transplant recipients with COVID-19.
Using death as the main outcome of interest, formal
quality assessment is shown in Table 1 using the
Newcastle-Ottawa Quality Assessment Scale.9
Quality assessment demonstrated consistent weak-
nesses in selection of control groups (e.g., home dialysis
patients on the transplant waiting list) and inadequate
control for additional confounding factors. Case series
are descriptive and do not make comparisons with a
control group, whereas single-center reports may yield
biased results when compared with the source popu-
lation. Kates et al.10 was susceptible to selection bias, as
participating centers may not have systematically
submitted all cases. Some studies did not report how
many patients had been discharged, meaning mortality
estimates may have been inaccurate due to misclassifi-
cation of patients who died after the end of follow-up,
but more recent reports had longer and more complete26follow-up. Although Boyarsky et al.18 and Vistoli
et al.19 had high response rates to their surveys, they
may not be completely reliable, as they were not linked
to individual patient records.
Study Populations
All studies identified by our search are listed in
Supplementary Table S4, along with other studies
reporting on $5 kidney transplant recipients. Our
searches of studies with $20 recipients with confirmed
COVID-19 and completed outcomes identified studies
from only 6 countries (France, Italy, Spain, Turkey,
United Kingdom, and United States); at least 5 of the 7
studies with patients from United States included cases
from New York City. There have been smaller pub-
lished studies not included in our review from
Belgium, China, Iran, Netherlands, Portugal, and
Switzerland.
We note that some studies had overlapping co-
horts: patients from Mohamed et al.20 would be
included in Ravanan et al.,11 whereas patients in
Pereira et al.21 would have been included in Lubetzky
et al.22 Some cases from Rodriguez-Cubillo et al.23 areKidney International Reports (2021) 6, 24–45
Table 1. Description of each study design and quality assessment using the Newcastle-Ottawa Quality Assessment Scale, listed by order of
online publication date
Study Study design Selection Comparability Outcome
Manganaro et al.16 Single-center case series **++ ** ***
Boyarksy et al.18 Cross-sectional national survey ***+ ** ***
Pereira et al.21 Two-center case series +*++ ** +**
Sánchez-Álvarez et al.12 National registry cohort ++*+ +* *+*
Vistoli et al.19 Cross-sectional national survey +**+ ** ***
Rodriguez-Cubillo et al.23 Single-center case series +*++ ** +++
Pascual. et al.13 National registry case series +*++ ** +**
Chen et al.27 Single-center case series +*++ ** +++
Mehta et al.28 Single-center case series +*++ ** +++
Bossini et al.25 Multicenter case series +*++ ** +++
Cravedi et al.17 Multicenter case series +*++ ** ++*
Chaudhry et al.26 Multicenter case series +*++ ** +**
Pérez-Sáez et al.14 National registry case series +*++ ** +++
Demir et al.24 Multicenter case series **++ ** +**
Lubetzky et al.22 Single-center case series +*++ ** +++
Bell et al. (preprint)15 National registry case series +*++ ** +++
Mohamed et al.20 Single-center case series +*++ +* +++
Kates et al.10 Multicenter case series **++ ** +++
Benotmane et al.29 Single-center case series +*++ ** +++
Ravanan et al.11 National registry cohort ++++ +* +++
From left to right, quality items were starred black if they fulfilled predefined criteria: selection was starred on representativeness of patients with the exposure of interest (kidney
transplant), selection of the nonexposed group, ascertainment of exposure, and demonstration that outcome of interest (death) was not present at start of the study; comparability was
starred on the study controlling for the exposure of interest, and any additional factor; outcome was starred on how the outcome was assessed, whether follow-up was long enough for
the outcome to occur, and whether loss to follow-up was adequate enough to be unlikely to introduce bias.
V Mahalingasivam et al.: COVID-19 and Kidney Transplantation CLINICAL RESEARCHlikely to have been included in the registry report by
Sánchez-Álvarez et al.,12 whereas Pascual et al.13 and
Pérez-Sáez et al.14 were reports of subgroup analyses
from this registry. Cravedi et al.17 excluded any pa-
tients from studies that had already been published,
but these were smaller studies not included in our
summary. Kates et al.10 did not report which centers
submitted data to its registry but there were more
than 50, of which >98% were from the United States;
our review includes 6 other studies with data from
the United States that may have overlapped. Some
centers from the United States and Italy reported in
our review are likely to have contributed to the
surveys published by Boyarsky et al.18 and Vistoli
et al.19Data Analysis
Data and results from each study are summarized in
Table 2. The 20 studies were published online between
April 10 and August 11, 2020; one was a preprint with
the remainder in journals. The last day of follow-up for
each study ranged from March 17 to May 31, 2020. The
studies ranged from 24 to 489 kidney transplant re-
cipients in total.
Patient Characteristics
Of the studies with available patient demographic data,
average age ranged from 45 years in Demir et al.24 to 66
years in Rodriguez-Cubillo et al.23 The percentage ofKidney International Reports (2021) 6, 24–45male patients ranged from 46% in Pascual et al.13 to
79% in Bossini et al.25
Clinical Presentation
Fever was common in studies, ranging from 52% to
95%; cough ranged from 49% to 78%, and dyspnea
from 28% to 70%. Gastrointestinal symptoms were also
reported, as high as 53% in Chaudhry et al.26 Four
studies reported data on acute kidney injury or graft
dysfunction at presentation, ranging from 28% in
Mohamed et al.20 to 77% in Chen et al.27 No report
described asymptomatic infection.
Baseline Immunosuppression Adjustment
A wide range of approaches was taken to adjust
immunosuppression both between and within the
studies. The dominant practice across other studies was
to favor withholding or reducing antiproliferative
drugs or mammalian target of rapapmycin inhibitor
over reduction in calcineurin inhibitor dose.
COVID-19 Therapy
Thirteen studies reported the use of COVID-19 thera-
pies. Hydroxychloroquine was used in 11 studies,
either alone or in combination with another therapy,
with the proportion of patients receiving the drug
ranging from 38% to 100%. Ten studies either started
corticosteroid therapy or increased dosage. High-dose
corticosteroid was reported in 6 studies for between
4% and 62% of patients. Remdesivir use was reported27





2020 Study population Setting
Timeframe





10 April All inpatients and outpatients with













































24 April All inpatients and outpatients with




















27 April Inpatients and outpatients who
tested positive for COVID-19 entered












 Age (y) median 60  13
 Sex: males w190/w286
(66%)a











 Mortality by age OR
1.09 (95% CI 1.06
– 1.13)
















3 June Reported COVID-19–positive
inpatients and outpatients








60 (57 hospitalized)  Transplanted between 1




 ICU 17/57 (30%)


























































































2020 Study population Setting
Timeframe






12 June Confirmed COVID-19 (RT-PCR)









29 (29 recovered to
discharge or died)
 Age (y) median 66 (IQR 59–
72)
 Sex: male 17/29 (59%)
 Time since transplant (mo) me-
dian 99 (IQR 26–171)
 Comorbidities: diabetes 11/29
(38%), obesity 15/29 (52%)
 Baseline IS: tacrolimus 19/29
(66%), ciclosporin 6/29
(21%), MPA 22/29 (76%),
mTORi 8/29 (28%), azathio-












 AKI 14/29 (48%)
 Oxygen requirement
7/29 (24%)





 Ferritin (ng/ml) me-
dian 647 (IQR
348–1682)











































 mTORi stopped 8/8
(100%)
 HCQ 27/29 (93%)
 Antibiotics 29/29
(100%)









19 June Inpatients with confirmed COVID-19
(RT-PCR) within 60 d of kidney
transplantation, entered to COVID-







24 (of 265 transplants
within 60 d) (do not
specify how many
recovered to discharge)
 Age: $65 y 12/24 (50%)
 Sex: male 11/24 (46%)
 Comorbidities: diabetes 12/24
(50%)
 Deceased donor 23/24 (96%)
 DGF 12/24 (50%)
 Acute rejection 2/24 (8%)
 Baseline IS: prednisone 24/24
(100%), tacrolimus 24/24


















 ICU admission 4/24
(17%)
 HCQ 22/24 (92%)
 Glucocorticoids 12/24
(50%)
 LPV/r 8/24 (33%)
 Tocilizumab 8/24
(33%)


























































































2020 Study population Setting
Timeframe





23 June Inpatients with confirmed COVID-19








30 (29 recovered to
discharge or died)
 Age (y) mean 56  12
 Sex: males 16/30 (53%)
 Race: African descent 22/30
(73%), Hispanic 5/30 (17%),
Caucasian 2/30 (7%), Asian
1/30 (3%)
 BMI (kg/m2) mean 28.7 (SD
6.9)
 Time since transplant (y) median
7 (IQR 4–14)
 Deceased donor 18/30 (60%)
 Cause of ESRD: hypertension 13/
30 (43%), diabetes 11/30
(36%), HIV 2/30 (7%), ADPKD
2/30 (7%), SLE 2/30 (7%)
 Comorbidities: diabetes 14/30
(47%), vascular diseases 11/
30 (37%), obesity 10/30
(33%), asthma/COPD 0/30
(0%)
 Baseline creatinine (mg/l) me-
dian 1.3 (IQR 1.0–1.8)
 CKD stage: 3 14/30 (47%), 4 1/
30 (3%), 2/30 (7%)
 Baseline IS: tacrolimus 26/30
(87%), ciclosporin 3/30
(10%), MMF 12/30 (40%),
prednisone 30/30 (100%)
 Baseline tacrolimus level (ng/ml)
















 LDH (units/l) me-
dian 294 (238–
427)
 CRP (mg/l) median
76 (IQR 44–147)
 ESR (mm/h) me-
dian 72 (IQR 58–
80)










 D ths 6/29
(21%)
 Mecha al ventila-
tion 7 (23%)
 RRT 4 (13%)





 MMF withheld 12/
12 (100%)
 High-dose MP 18/
30 (60%)
 HCQ þ AZM 30/30
(100%)

































































































2020 Study population Setting
Timeframe















23 June Attendees to ED with confirmed
COVID-19 (RT-PCR) of 44 who









34 (33 recovered to
discharge or died)
 Age (y) median 59 (IQR 53–
64)
 Sex: male 22/34 (65%)
 Race: African American 15/34
(44%), Hispanic 8/34 (24%),
Asian 2/34 (7%), white 7/34
(21%), other 2/34 (7%)
 BMI (kg/m2) median 27.4 (IQR
24.0–31.5)
 Time since transplant (mo) me-
dian 37 (IQR 19–54); within 12
mo 14/30 (41%)
 Deceased donor: 27/34 (79%)
 Baseline IS: tacrolimus 29/34
(85%), cyclosporin 1/34
(3%), MMF 33/34 (97%),
belatacept 6/34 (18%), ever-




























 LOS (d) median 10
(IQR 5–16)
 AKI during admis-
sion 18/34 (53%)









 CNI held 0/30
(0%)
 HCQ 33/34 (97%)
 AZM 27/34 (79%)
 Tocilizumab or recruited




6 July Symptomatic inpatients and
outpatients assessed either in ED or











53 (45 hospitalized; 42
recovered to discharge or
died)
 Age (y) median 60 (IQR 50–
67)
 Sex: males 42/53 (79%)
 Cause of ESRD: PKD 12/53
(23%), IgA 8/53 (15%), other

















 Withdrawal of usual
IS 42/45 (93%)
 MMF withdrawn &
CNI halved 3/45
(7%)
 Started or increased





 LPV/r 18/45 (40%)
 DRV/r 14/45 (31%)


























































































2020 Study population Setting
Timeframe
in 2020 Total number of cases Patient characteristics Clinical presentation Outcomes
Baseline IS
adjustment COVID-19 therapy
(9%), other 5/53 (9%), not
determined 17/53 (32%)
 Comorbidities: diabetes 11/53
(21%), cardiac diseases 10/53
(19%), previous DVT 4/53
(8%), other 4/53 (8%)
 Time since transplant (y) median
9 (IQR 4–16)
 Deceased donor 48/53 (91%)
 Induction IS: ATG 17/38 (45%),
basiliximab 14/38 (37%),
alemtuzumab 6/38 (38%), other
1/38 (3%)
 Baseline IS: tacrolimus 31/53
(58%), cyclosporin 17/53
(32%), MMF 32/53 (60%),
mTORi 6/53 (11%), glucocor-
ticoid 30/53 (57%)
 Baseline creatinine (mg/dl) me-
dian 1.8 (IQR 1.5–2.4)
 GI symptoms 9/53
(17%)





 Time from symp-
toms to presenta-
tion (d) median 7
(IQR 4–10)







l) median 0.6 (IQR
0.4–1.1)
 LDH (units/l) me-
dian 263 (IQR
213–323)












 ARDS 27/45 (60%)







(IQR 20 to 7)
(from 1 center ¼
28 patients)
 LOS (d) median 11
(IQR 7–16)















 mTORi withdrawn &
CNI halved 1/8
(13%)
 CNI halved 1/8
(13%)
 Started or increased






































































































2020 Study population Setting
Timeframe








10 July Inpatients with confirmed COVID-19
(RT-PCR) participating in the
TANGO consortium (www.
tangoxstudy.com) (excluded











144 (do not specify how
many recovered to
discharge)
 Ages (y) median 62 (IQR 52
– 69)
 Sex: male 94/144 (65%)
 Race: Hispanic 56/144 (40%),
White 43/144 (31%), African
American 35/144 (25%)
 Comorbidities: diabetes 75/144
(52%), obesity 71/144 (49%),
heart disease 41/144 (28%),
lung disease 27/144 (19%),
cancer 22/144 (15%), smoking
history 39/144 (27%), HIV 3/
144 (2%), ACEI 20/144
(14%), ARB 24/144 (17%)
 Cause of ESRD: diabetes 43/144
(30%), glomerular disease 25/
144 (16%), hypertension 20/
144 (14%), PKD 13/144 (9%)
 Time since transplant (y) median
5 (IQR 2–9), <1 y 23/144
(16%)
 Deceased donor 112/144
(78%)
 Baseline IS: tacrolimus 131/144
(91%), MMF 111/144 (77%),










 Symptoms onset to
admission (d) me-
dian 6 (IQR 3–8)
 WCC (109/L) me-









 CRP (mg/l) median
41 (IQR 12–125)






















 ECMO 3/144 (2%)
 AKI 74/144 (51%)
 Symptom onset to
death (d) median
15 (IQR 8–22)
 Symptom onset to
discharge (d) me-
dian 22 (IQR 15–
35)
 Follow-up (d) me-















 LPV/r 7/144 (5%)
 DRV/r 3/144 (2%)
 Darunavir-cobisistat 1/
144 (1%)


























































































2020 Study population Setting
Timeframe





12 July All inpatient and outpatient SOT












38 (26 hospitalized)b  Age (y): median 61.5 (IQR
52–70)
 Sex: males 26/38 (68%)
 Race: Black 31/38 (82%)
 Comorbidities: COPD 5/38
(13%), CKD 35/38 (92%),
heart failure 8/38 (21%),




(8%), smoking history 7/38
(18%)




 Fever 22/38 (58%)
 Dyspnea 21/38
(55%)









(d) median 7 (IQR
2–10)




l) median 0.5 (IQR
0.4–0.8)





















 Hospital LOS (d)




12 July Inpatients identified through
national COVID-19 registry with
confirmed COVID-19 (RT-PCR) who
received tocilizumab based on
individual hospital protocols for
increased disease severity. All
patients had at least one of the
following: increased IL-6; increase












80 (of 468 included in the
registry) (80 recovered to
discharge or died)
 Age (y): mean 59 (SD 12)
 Sex: Males 54/80 (68%)
 Race: Caucasian 71/80 (89%)
 Comorbidities: diabetes 23/80
(29%), lung disease 7/80
(9%), IHD 13/80 (16%), can-
cer history 17/80 (22%), BMI










 ICU admission 24/
80 (30%)
 NIV 33/80 (44%)
 Mechanical ventila-
tion 19/80 (24%)









 Tocilizumab > 1dose
16/80 (20%)
 HCQ 79/80 (99%)
 AZM 59/80 (74%)


























































































2020 Study population Setting
Timeframe
in 2020 Total number of cases Patient characteristics Clinical presentation Outcomes
Baseline IS
adjustment COVID-19 therapy
Additional patients were identified
after contacting centers
ACEI/ARB 26/80 (33%),
smoking history 17/80 (21%)
 Cause of ESRD: diabetes 15/80
(19%), vascular 7/80 (9%),
glomerular 17/80 (21%), PKD
14/80 (18%)
 Time since transplant (mo) me-
dian 72 (IQR 17 – 165)
 Re-transplantation 21/80 (26%)
 Induction: ATG 33/80 (41%)
 Baseline IS: CNI 66/80 (83%),
prednisolone 73/80 (91%),
MMF 64/80 (80%), mTORi 14/
80 (18%)
 GI symptoms 38/80
(48%)
 CXR changes 78/80
(98%)
 Symptom onset to
admission (d)






(IQR 91 – 97)
(n ¼ 40)
 WCC (109/l) mean
6.8 (SD 3.1)
 Lymphocytes (109/
l) mean 0.8 (SD
0.6)





 IL-6 (pg/ml) me-
dian 52 (IQR 33–
110)
 LDH (units/l) me-
dian 335 (IQR
257–485)




 AKI 36/80 (45%)
 AKI requiring dial-
ysis 15/80 (19%)
 Acute rejection 1/80
(1%)
 Time admission to
ICU (d) median 7
(IQR 4–12)
 Follow-up time (d)
median 25 d (IQR
17–35)
 Other antibiotic 61/80
(76%)
 Steroids 64/80 (80%)
 i.v. Ig 12/80 (15%)
 Interferon 5/80 (6%)
 LPV/r or remdesevir 39/
80 (49%)
 Anakinra 6/80 (8%)


























































































2020 Study population Setting
Timeframe




















44 (1 excluded as
“without typical findings”,
3 lost to follow-up) (39
hospitalized - do not
specify how many
recovered to discharge)
 Age (y): mean 45 (SD 15)
 Sex: male 20/40 (50%)
 Cause of ESRD: hypertension 4/
40 (10%), diabetes 2/40 (5%),
chronic GN 13/40 (33%)
 Comorbidities: lung disease 3/40
(8%), ACEI/ARB 18/40 (45%),
hypertension 26/40 (65%)
 Time since transplant (mo) me-
dian 75 (IQR 32–128)
 Deceased donor 5/40 (13%)
 Induction IS: ATLG 22/40 (55%),
basiliximab 3/40 (8%)
 Baseline IS: tacrolimus 31/40
(78%), cyclosporine 5/40





















l) median 0.7 (IQR
0.5–1.0)
 CRP (mg/l) median
45 (IQR 24–88)











 NIV 4/40 (10%)
 Mechanical ventila-
tion 6/40 (15%)
 Follow-up time (d)
32 (IQR 23–44)
 LOS (d) median 9












 Anakinra 3/40 (8%)
 Antibiotics 24/40
(60%)


























































































2020 Study population Setting
Timeframe







17 July Consecutive inpatients and








54 (39 hospitalized; 37
recovered to discharge or
died)
 Age (y): median 57 (range 29 –
83)
 Sex: male 38/54 (70%)
 Race: white 17/54 (31%), His-
panic 17/54 (31%), black 13/
54 (24%), Asian 6/54 (11%),
Middle Eastern 1/54 (2%)
 BMI (kg/m2): (median) 28 (IQR
18–43)
 Comorbidities: diabetes 16/54
(30%), cardiovascular disease
19/54 (35%), stroke 4/54
(7%), lung disease 8/54
(15%), antihypertensives 50/
54 (93%), ACEI/ARB 19/54
(37%), smoking 12/54 (22%)
 Baseline creatinine (mg/dl) mean
1.5 (SD 0.7)
 Cause of ESRD: hypertension 11/
54 (20%), diabetes 14/54
(26%), GN 13/54 (24%), lupus
2/54 (4%), PKD 3/54 (6%)
 Time since transplant (y): me-
dian 4.7 (range 0.3 -35)
 Deceased donor 17/54 (31%)
 IS induction: T-cell depleting
agent 39/54 (72%)
 Baseline IS: steroids 22/54
(41%), CNI 52/54 (96%),
belatacept 1/54 (2%), MMF
52/54 (96%), mTORi 2/54
(4%)
All patients:












 Time symptoms to
diagnosis (d):






mean 2.6 (SD 2.3)










 Death 7/39 (18%)
 Mechanical ventila-
tion 11/39 (28%)
 AKI 20/39 (51%)
 RRT 4/39 (10%)









 Follow-up (d) me-













 MMF halved 15/52
(29%)
 MMF withheld 24/
52 (46%)





 HCQ 31/39 (79%)
 Remdesivir 2/39 (5%)
 IL-6 receptor inhibitor 2/
39 (5%)
 Convalescent plasma 1/
39 (3%)




 HCQ 1/15 (7%)
 AZM 5/15 (33%)
 Doxycycline 1/15 (7%)


























































































2020 Study population Setting
Timeframe
in 2020 Total number of cases Patient characteristics Clinical presentation Outcomes
Baseline IS
adjustment COVID-19 therapy
 Ferritin (ng/ml) me-
dian 1498 (IQR
383–2646)
 IL-6 (pg/ml) me-





 AKI 20/39 (51%)
Bell et al.15 21 July
(posted)
Notified confirmed COVID-19 as
identified through the Scottish Renal









24 (of 3286 functioning
kidney transplants)
 Age (y): 20–44 4/24 (17%),
45–64 12/24 (50%), 65–
74 5/24 (21%), $75 3/
24 (13%)
 Sex: male 13/24 (54%)
 Cause of ESRD: GN 3/24 (13%),
interstitial 12/24 (50%), Multi-
system 3/24 (13%), diabetes 3/
24 (13%)
 Time since transplant (y): <1 0/
24 (0%), >10 14/24 (58%)
 Scottish Index of Multiple Depri-
vation: 1 (most deprived) 7/24
(29%), 5/24 (21%), 4/24






31 July Consecutive inpatients and








28 (of 1434 functioning
transplants) (25
hospitalized – 25
recovered to discharge or
died); comparison with
32 patients active on
transplant waiting list (of
321) (14 hospitalized)
 Age (y) median 57 (range
25–72)
 Sex: male 16/28 (57%)
 Time since transplant (mo) me-
dian 39 (range 1–227 mo);
within 1 y 7/28 (25%); within 3
mo 1/28 (4%)
 Donor: deceased 22/28 (79%)
 BMI (kg/m2) median 28 (range
19–38)

















 ICU 5/25 (20%);
died 4/5 (80%)










































































































2020 Study population Setting
Timeframe
in 2020 Total number of cases Patient characteristics Clinical presentation Outcomes
Baseline IS
adjustment COVID-19 therapy
(37%), IHD 5/28 (18%),
chronic lung disease 4/28
(14%), chronic liver disease 0/
28 (0%), PVD 1/28 (4%)
 Induction IS: IL2RA 21/27
(78%), ATG 6/27 (22%)d
 Baseline IS: tacrolimus þ MMF þ
prednisolone 16/27 (59%),
ciclosporin þ MMF þ predniso-
lone 5/27 (19%), tacrolimus þ
azathioprine þ prednisolone 3/
27 (11%), cyclosporin þ pred-
nisolone 2/27 (7%),
tacrolimus þ prednisolone 1/27
(4%)d
 Baseline creatinine (mmol/l) me-
dian 155 (range 68–356)




 Hb (g/l) median
108 (range 81–
157)

















7 August Any inpatient or outpatient SOT
recipient with confirmed COVID-19
(RT-PCR) reported through an














 Age (y) 56 (IQR 46–66)
 Sex: male 186/318 (59%)
 Race: Asian/Pacific Islander 18/
318 (6%), black 150/318




 Geographic location: United
States – Northeast 151/318
(48%), Midwest 72/318
(23%), South 46/318












 GI symptoms 156/
318 (49%)
 WCC (x 109/l) me-





















 AZM 110/318 (35%)
 Anti-IL6 39/318 (12%)


































































































2020 Study population Setting
Timeframe
in 2020 Total number of cases Patient characteristics Clinical presentation Outcomes
Baseline IS
adjustment COVID-19 therapy
 Time since kidney transplant (y)
median 5 (IQR 2–10)
 Transplanted in 2020 9/318
(3%)
 Comorbidities: coronary artery
disease 68/318 (21%), heart
failure 30/318 (9%), diabetes
170/318 (54%), CKD 134/
318 (42%), haemodialysis 25/
318 (8%), chronic lung dis-
ease 29/318 (9%), malig-
nancy 8/318 (3%), HIV 5/318
(2%), BMI >30 kg/m2 116/
318 (37%)
 $2 of age >65 y, heart failure,
chronic lung disease and obesity
53/318 (17%)
 Baseline IS: CNI þ
antiproliferative þ steroid
176/318 (55%), CNI þ
steroid 49/318 (15%),




 Recently augmented IS 26/318
(8%)
 Blood type: A 95/318 (34%), B
49/318 (18%), AB 14/318
(5%), O 118/318 (43%)
 Neutrophils (x 109/
l) 4.3 (3.1–6.3)















 New RRT 42/318
(13%)
 Acute rise in LFT
>3x ULN 21/318
(7%)
 Acute MI 7/318
(2%)






 Acute TCMR or AMR
1/318 (0%)








10 August Consecutive inpatients with COVID-












40  Age (y) median 64 (IQR 55–
68)
 Sex: male 31/40 (78%)










 Severe disease (ox-
ygen requirement





 CNI withdrawal 15/
35 (43%)
 AZM 26/40 (65%)
 Other antibiotics 40/40
(100%)
 LPV/r 1/40 (3%)
 HCQ 15/40 (38%)


























































































2020 Study population Setting
Timeframe




disease 16/40 (40%), respi-
ratory disease 9/40 (23%),
diabetes 19/40 (48%); ACEI/
ARB 15/40 (38%)
 Time since kidney transplant (y)
median 7 (IQR 3–15)
 Induction IS: ATG 18/40 (44%),
anti-CD25 19/40 (46%), none
3/40 (7%)
 Baseline IS: tacrolimus 21/40
(53%), ciclosporin 14/40
(35%), MMF/MPA 34/40
(85%), mTORi 6/40 (15%),
azathioprine 1/40 (3%), corti-
costeroids 23/40 (58%), bela-





























 Antifungal 1/40 (3%)
Ravanan
et al.11
11 August SOT recipients with functioning graft
as of 1 February with notified
COVID-19 (RT-PCR) as identified
through the NHS Blood and
Transplant registry with linkage to
Public Health England and the NHS
Digital Tracing Service
England, UK 1 February
to 20 May










ACEI/ARB, angiotensin-converting-enzyme inhibitor/angiotensin II-receptor blocker; AKI, acute kidney injury; AMR, antibody-mediated rejection; ARDS, adult respiratory distress syndrome; ATG, anti-thymocyte globulin; AZM, azithromycin; CAKUT,
congenital abnormality of the kidneys and urinary tract; CI, confidence interval; CKD, chronic kidney disease; CNI, calcineurin inhibitor; COPD, chronic obstructive pulmonary disease; COVID-19, Coronavirus Disease 2019; CQ, chloroquine; CRP, C-
reactive protein; CT, computed tomography; CXR, chest x-ray; DGF, delayed graft function; DRV/r, darunavir/ritonavir; DVT, deep vein thrombosis; ECMO, extracorporeal membrane oxygenation; ED, emergency department; ESRD, end-stage renal
disease; GI, gastrointestinal; GN, glomerulonephritis; HCQ, hydroxychloroquine; HIV, human immunodeficiency virus; ICU, intensive care unit; IHD, ischaemic heart disease; IL-6, interleukin-6; IQR, interquartile range; IS, immunosuppression; LDH,
lactate dehydrogenase; LOS, hospital length of stay; LPV/r, lopinavir/ritonavir; MMF, mycophenolate mofetil; MP, methylprednisolone; MPA, mycophenolic acid; mTORi, mammalian target of rapamycin inhibitor; NHS, National Health Service; NIV, non-
invasive ventilation; OR, odds ratio; PKD, polycystic kidney disease; RCT, randomized controlled trial; RRT, renal replacement therapy; RT-PCR, reverse transcriptase polymerase chain reaction; SD, standard deviation; SOT, solid organ transplant;
TCMR, T-cell mediated rejection; ULN, upper limit of normal; WCC, white cell count.
aData reported as percentages of a total 868 patients receiving RRT.
bUnclear how many patients were discharged, as authors reported 26 discharged but also reported 7 died and 6 remained ventilated.
cAntimetabolite reported withheld in 40 of 40, but only 36 of 40 were on MMF at baseline.
dData available for 27 of 28 patients (missing for 1 patient).





















































































CLINICAL RESEARCH V Mahalingasivam et al.: COVID-19 and Kidney Transplantationin only a few studies, in a small number of patients.
Eleven studies reported the use of an anti–interleukin-6
therapy. Pérez-Sáez et al.14 described the experience of
tocilizumab use based on inpatient cases entered to the
Spanish Society of Nephrology registry.
Outcomes
Inpatient mortality was calculated where possible as a
proportion from patients with completed outcomes
(i.e., death or recovery to discharge), with the intention
of reducing bias by misclassification of patients who
remain hospitalized but may die later. In the largest
national registry reports, mortality was 43% among
mostly inpatients with completed outcomes in Sánchez-
Álvarez et al.12 from Spain up until April 11, and 26%
in mostly inpatients reported by Ravanan et al.11 from
England up until May 20, although the number of pa-
tients who may subsequently recover from both studies
was not known. In the largest multicenter series, Cra-
vedi et al.17 reported 32% mortality in 144 inpatients,
although it did not specify how many recovered to
discharge, whereas Kates et al.10 reported 28-day mor-
tality as 18% from its dataset in which 254 of 318 pa-
tients were hospitalized. Of other studies from which
inpatient mortality could be calculated, mortality was 7
of 39 patients (18%) in Lubetzky et al.22 across New
York, 6 of 29 patients (21%) in both Rodriguez-Cubillo
et al.23 in Madrid and Chen et al.27 in New York City,
15 of 42 patients (36%) in Bossini et al.25 in Brescia, and
9 of 25 patients (36%) Mohamed et al.20 in London.
Cravedi et al.17 found 7% increased mortality in
people aged >60 years compared with those aged #60
years. In subgroup reports from the national registry in
Spain, Pascual et al.13 reported 46% mortality among
patients within 60 days of transplantation, whereas
Pérez-Sáez et al.14 reported 33% mortality among pa-
tients with severe COVID-19 treated with tocilizumab.
The proportion of patients requiring intensive care
was variable, from 9% of inpatients across Spain ac-
cording to early registry data,12 to 42% of inpatients in
the large multicenter series report by Kates et al.10
including 34% requiring mechanical ventilation.10
Acute kidney injury was common, ranging from 41%
in Kates et al.10 with 13% requiring extracorporeal renal
replacement therapy, to 53% in Mehta et al.,28 although
none required renal replacement therapy. There were
very few reports of acute rejection, with only 1 case of
318 in Kates et al.10 Benotmane et al.29 reported RNAe-
mia in 26% and seropositivity in 100% of survivors.DISCUSSION
Our systematic review of the early literature up to
August 11, 2020, suggests that kidney transplant42recipients hospitalized with COVID-19 experience poor
outcomes, especially in the early post-transplant period.
The limitations of the literature so far require
appreciation. Over time, published studies evolved
from reports from a small number of centers, to larger
multicenter studies and national registries. To reduce
bias by smaller studies, we reported only those
studies with completed outcomes for at least 20 kid-
ney transplant recipients with confirmed COVID-19.
Small studies may be more likely to be published by
centers who accumulate more complex or unwell pa-
tients or by centers who are affected particularly
unfavorably, both of which may introduce important
bias; they may also exert a period effect, reflecting
more overwhelming circumstances in the earlier
stages of the pandemic.
Variation in reported mortality also could be due to
strong period effects, with differences in thresholds for
hospitalization, availability of resources, and manage-
ment practices. Data from Sánchez-Álvarez et al.12
found mortality of 43% from the Spanish Society of
Nephrology COVID-19 registry in which 94% were
inpatients. However, this is likely to be exaggerated as
this was an early report based on data reported up to
April 11, and approximately 147 patients remained
alive but not yet recovered so were not included in our
mortality calculation; fewer patients were admitted to
intensive care unit compared with other reports which
also may be an important period effect related to
stretched resources.
The other large national registry report was Rav-
anan et al.,11 who identified all solid organ transplant
recipients from the National Health Service Blood and
Transplant and linked this to confirmed COVID-19
cases through Public Health England and the Na-
tional Health Service Digital Tracing Service. Of more
than 30,000 prevalent kidney or kidney-pancreas re-
cipients in England, there were 489 cases of COVID-19
of whom 128 died (26%) up to May 20.11 This was
compared with deaths in 18 of 188 (10%) patients
waitlisted for transplantation but this comparison
should be treated with caution, as many of these will
have been in-center hemodialysis patients with more
access to testing for milder or asymptomatic disease
than transplant recipients in the community during
the period of study. It was not possible to distinguish
inpatients and outpatients from the available data
sources, but as data were collected up to May 20, most
cases were likely to be inpatients.
Large multicenter series were published by Cra-
vedi et al.17 and Kates et al.10 Cravedi et al.17 re-
ported data for inpatients with COVID-19 from
centers in Italy, Spain, and the United States already
participating in the TANGO consortium, anKidney International Reports (2021) 6, 24–45
V Mahalingasivam et al.: COVID-19 and Kidney Transplantation CLINICAL RESEARCHinternational network formed initially to investigate
the recurrence of glomerular disease after trans-
plantation. Kates et al.10 reported outcomes from a
registry hosted by the University of Washington to
which cases were submitted from >50 centers, >98%
of which were from United States after invitations
through the American Society of Transplantation and
American Society of Transplant Surgeons.10 Entered
data were not independently verified and its repre-
sentativeness is uncertain as the extent to which
cases from participating centers were systematically
submitted is not known, with the authors acknowl-
edging susceptibility to bias.
Studies from the United States reported high pro-
portions of black patients, although no study investi-
gated for associations between ethnicity or other
socioeconomic factors with outcomes. From all solid
organ transplant recipients in England, 38 of 129 Asian
recipients (30%) and 27 of 95 (28%) black recipients
died, compared with 79 of 334 white recipients (24%).
In total, 2.4% of Asian recipients and 3.6% of black
recipients have been diagnosed with COVID-19,
compared with 1.0% of white recipients.11
The withdrawal of antiproliferative drugs such as
mycophenolate, an inhibitor of T- and B-cell prolifer-
ation, was practiced almost universally, in keeping
with expert consensus for even mild disease.30,31 Our
review highlighted the myriad of different manage-
ment strategies used in different centers, including
antivirals, hydroxychloroquine, corticosteroids, and
tocilizumab. Establishing the effectiveness of therapies
requires well-designed clinical trials; as high-risk pa-
tients, kidney transplant recipients may benefit from
both prophylactic and therapeutic trials. The RECOV-
ERY trial demonstrated mortality benefit in treatment
with dexamethasone 6 mg daily for patients with
COVID-19 requiring oxygen in June 2020, with the
World Health Organization consequently recommend-
ing the use of systemic corticosteroids in severe and
critical cases.6,32 The RECOVERY trial has stopped
recruiting patients to its lopinavir/ritonavir arm
because of lack of benefit.33 Few patients in studies
were reported to have been treated with remdesivir.
Acute kidney injury was seen in several studies,
although not all studies reported their definition and
alternative terminology such as “renal failure” was also
mentioned. Acute kidney injury is not uncommon in
COVID-19, and its pathophysiology remains uncertain,
but direct parenchymal infection and microangiopathy
mediated by complex inflammatory processes have
been suggested.34 In transplant kidneys, there may be
additional mechanisms, such as acute rejection from
underimmunosuppression, or calcineurin inhibitor
toxicity through drug-drug interactions (e.g.,Kidney International Reports (2021) 6, 24–45lopinavir/ritonavir); however, there were few reports
of acute rejection in our review, but there may have
been less investigation for this because of unwilling-
ness to augment immunosuppression if it were diag-
nosed; we did not identify any histopathological series;
and case reports of biopsies are prone to bias so sys-
tematic cross-sectional or longitudinal study designs
would need to be considered. Studies in the coming
months and years will need to address the longer-term
impact of COVID-19 on graft function and permanent
graft loss.
Pascual et al.13 reported deaths in almost half the
patients in Spain who acquired COVID-19 within 60
days of transplantation (11 of 24 [of 265 transplants in
total]) up to April 18. Nearly all were recipients of
deceased donor transplants with delayed graft function
reported in half, but the authors did not report whether
SARS-CoV-2 infection was acquired in health care set-
tings or in the community. Although these findings are
alarming, it will also have been affected by period effects
from the start of the pandemic and there may now be
opportunities to better minimize transmission in acute
transplantation through planning and infrastructure.
Several deceased- and live-donor programs were sus-
pended with the aim of preventing high-risk patients
acquiring SARS-CoV-2 infection perioperatively,
limiting the use of lymphocyte-depleting antibodies as
induction agents or in treatment of severe rejection, and
avoiding use of limited inpatient resources. As services
are restored, outcomes should be audited closely, and
the risks and benefits should be nevertheless considered
on an individualized basis given the apparent increased
risk with heightened immunosuppression.
As the pandemic continues, we will need to use more
systematic national and international registries with
appropriate control groups and linkage to other sources,
such as community test results and hospital records, to
allow timely, large-scale analyses that can better inform
policies and practices. Serological surveys of transplant
recipients using validated antibody assays could be
valuable in capturing the prevalence of asymptomatic
and mild infection that did not result in inpatient
admission or community viral RNA testing; such sur-
veys will be important to obtain more accurate mortality
and hospitalization estimates, follow-up potential
longer-term complications, and identify the factors that
are associated with more favorable outcomes.
Limitations
In the absence of available data, we were unable to
undertake time-to-event analysis, therefore we report
mortality as a proportion of patients with completed
outcomes to avoid misclassification of patients who
remain hospitalized but may die after surviving the43
CLINICAL RESEARCH V Mahalingasivam et al.: COVID-19 and Kidney Transplantationstudy period. However, this might be biased in the
opposite direction if most of those who remained hos-
pitalized were patients who were slowly recovering
and more likely to survive.
Our searches included studies in English or Chinese
only, with studies meeting inclusion criteria from
France, Italy, Spain, Turkey, the United Kingdom, and
the United States only. Searches in more languages may
have resulted in a broader perspective, including more
experiences in middle-income economies. As well as
studies from Europe and North America, there were
studies published from China and Iran from early in the
pandemic that did not fulfill our criteria for inclusion
because of smaller numbers of confirmed cases. It
would be beneficial to obtain updated reports from
centers such as these, as well as others in Africa, Asia,
and Latin America.
The Newcastle-Ottawa Quality Assessment Scale was
of limited value in objective quality assessment. It is
designed to be semi-quantitative, but the crude
equivalence of all the constituent assessment items may
be misleading.
CONCLUSION
Our review of the literature in the early phase of the
COVID-19 epidemic suggests that hospitalized kidney
transplant recipients with COVID-19 are at a high risk
of death. The quality of observational data is
improving. Detailed and comprehensive data collection
through registries and linkage with health records will
be necessary to conduct analyses of risk factors for
adverse outcomes, not least given the risks of stopping
immunosuppression. Indeed, to optimize clinical care,
we should ensure that nonhospitalized patients are
included and existing registries are supported and
commissioned to answer important questions that
affect screening and management.
We are reassured that we have developed a repro-
ducible search strategy that can be effectively rede-
ployed at appropriate intervals during the pandemic
and beyond to be able to conduct meta-analyses of
accumulating data in the future.DISCLOSURE
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